Orchid Pharma advances on receiving ANDA approval for Aripiprazole Tablets

13 Dec 2017 Evaluate

Orchid Pharma is currently trading at Rs. 18.30, up by 0.85 points or 4.87% from its previous closing of Rs. 17.45 on the BSE.

The scrip opened at Rs. 17.05 and has touched a high and low of Rs. 18.30 and Rs. 17.05 respectively. So far 80,235 shares were traded on the counter.

The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 39.70 on 18-Apr-2017 and a 52 week low of Rs. 16.70 on 06-Sep-2017.

Last one week high and low of the scrip stood at Rs. 18.50 and Rs. 17.05 respectively. The current market cap of the company is Rs. 156.03 crore.

The promoters holding in the company stood at 26.68%, while Institutions and Non-Institutions held 4.78% and 68.54% respectively.

Orchid Pharma has received ANDA approval from USFDA for Aripiprazole Orally-Disintegrating Tablets USP, 10 mg and 15 mg. Aripiprazole Orally-Disintegrating Tablets are atypical antipsychotic, indicated in the treatment symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression).

Orchid Pharma is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients and finished dosage forms. It is also engaged in research of new drugs.


Orchid Pharma Share Price

865.95 0.80 (0.09%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×